BriaCell Therapeutics Corp.
BCTX · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9 | $10 | $7 | $8 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $12 | $9 | $10 |
| Operating Income | -$12 | -$12 | -$9 | -$10 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | $0 | $1 |
| Pre-Tax Income | -$11 | -$11 | -$9 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$11 | -$9 | -$9 |
| % Margin | – | – | – | – |
| EPS | -4.31 | -5.87 | -23.33 | -33.57 |
| % Growth | 26.6% | 74.8% | 30.5% | – |
| EPS Diluted | -4.31 | -5.87 | -23.33 | -33.57 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 3 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$11 | -$9 | -$9 |
| % Margin | – | – | – | – |